Skip to main content

Steroids

Long Term Safety and Efficacy of Tacrolimus in Lupus Nephritis

Jan 13, 2021

Takeuchi et al has published their large experience with long-term tacrolimus use in lupus nephritis patients showing its real-world safety and efficacy.



This oopen-label, observational, cohort study from 275 sites in Japan, included 1355 systemic lupus erythematosus (SLE) patients

Read Article

Corticosteroid Use Hikes CV Risks in Rheumatic Patients

Jan 11, 2021

UK Clinical Practice Research Datalink population study shows that patients with immune-mediated inflammatory diseases, such as RA, PMR, GCA and IBD, have an augmented risk of CV outcomes with glucocorticoid use; even lower doses had a near doubling of their underlying CVD risk.

Read Article
Study of 2050 Northern Italian arthritis clinic pts; where 1.1-1.4% of population developed COVID-19. Steroid use was independently associated with increased COVID risk (adj OR 1.23 to 3.20). But Rx w/ ts/bDMARDs had reduced risk (adj OR 0.46).

Dr. John Cush RheumNow ( View Tweet)

Jan 05, 2021

Update on Polymyalgia Rheumatica and Giant Cell Arteritis (Best of 2020)

Dec 31, 2020

JAMA has published a clinical update of recent studies on GCA. While PET/CT scanning are novel means of demonstrating activity, they have not changed the diagnostic approach to GCA or PMR and although there are no new proven treatment strategies for PMR beyond glucocorticoids, the FDA has

Read Article

ACR 2020 Reproductive Guidelines - Lactation Guidance (Best of 2020)

Dec 30, 2020

In this third excerpt from the ACR guidelines on managing reproductive health issues in rheumatic disease patients, we present recommendations regarding the use of glucocorticoids and guidance on lactation and medication use post-partum.

Read Article
COVID: DMARDs, Steroids, a Vaccine - and how long will this continue? Dr. Winthrop reviews all things COVID-related including abstract L01, steroids and DMARDs, vaccination status - and how long this pandemic will last.
Dr. John Cush RheumNow ( View Tweet)
Dec 19, 2020

COVID Risks in Systemic Autoimmune Patients

Dec 15, 2020

There have been conflicting reports of whether rheumatic patients have greater risks once they are infected with COVID-19. This claims cohort analysis suggests a mixed picture. 

Read Article

Mortality in Low Dose Prednisone

Dec 08, 2020

Upon release of the new ACR 2020 Pharmacologic Treatment Recommendations for the Management of Rheumatoid Arthritis, many practitioners were surprised that the new guidelines recommended against glucocorticoid initiation at disease onset.

Read Article
Check out our latest article from Richard Conway ( @RichardPAConway) #ACR20 The tantalising prospect of glucocorticoid-free treatments for systemic vasculitis https://t.co/VG1ah3Nq5c https://t.co/js3l527VHg
Dr. John Cush RheumNow ( View Tweet)
Dec 06, 2020
#BestACR20Tweets RT @RichardPAConway :Dr Cid presents phase 2 trial of anti-GM-CSF agent mavrilimumab in combination with steroids in GCA. 70 patients. Sustained remission at week 26 in 83.2% of mavrilimumab vs 49.9% of placebo p=0.0038.
Dr. John Cush RheumNow ( View Tweet)
Dec 02, 2020

The tantalising prospect of glucocorticoid-free treatments for systemic vasculitis

Nov 30, 2020

Glucocorticoids are a highly effective treatment in systemic vasculitis but are also a significant cause of long-term harm in the form of treatment related adverse events. Virtually every vasculitis patient treated with traditional glucocorticoid regimes suffers from these. These are not

Read Article

What’s new in knee osteoarthritis that matters?

Are intra-articular steroid injections effective in symptomatic knee OA? Do they accelerate cartilage loss? Does weight less actually help? Do we have DMARDs for knee OA? Insights from 2020 ACR Convergence.

Read Article
#BestACRTweets20 RT @RHEUMarampa : IgG4-RD tx: GCs are mainstay tx starting at 30-40mg/d tapered gradually but 30% of pts will have recurrences Potential therapeutic targets to ⬇GC toxicity ✏B cell/plasmablasts (promising) ✏T cells (anecdotal) #ACR20 https://t.co/h

Dr. John Cush RheumNow ( View Tweet)

Nov 20, 2020

RheumNow Podcast – ACR 2020 Epilogue (11.20.20)

Nov 20, 2020

Dr. Jack Cush reviews a few more ACR 2020 abstracts and presents a new plan to learn or take in ACR20 content.

Read Article
"The tantalising prospect of glucocorticoid-free treatments for systemic vasculitis" by Dr. Richard Conway ( @RichardPAConway) https://t.co/VG1ah3Nq5c https://t.co/jORhfQn3EC
Dr. John Cush RheumNow ( View Tweet)
Nov 17, 2020
Mortality in Low Dose Prednisone by Dr. Eric Dein ( @ejdein1). #ACR20 https://t.co/y6dL9V6iDC https://t.co/e7119ymgiq
Dr. John Cush RheumNow ( View Tweet)
Nov 16, 2020
Read our news article "Ten-Year Analysis of Low-Dose Glucocorticoids in early RA" by Meral K. El Ramahi ( @MeralElRamahiMD) #ACR20. https://t.co/S9rOHc0864 https://t.co/6X4owP6pF0
Dr. John Cush RheumNow ( View Tweet)
Nov 13, 2020
Quick Read! Mortality in Low Dose Prednisone by Dr. Eric Dein ( @ejdein1). #ACR20 https://t.co/y6dL9V6iDC https://t.co/ZFpxoTH07p
Dr. John Cush RheumNow ( View Tweet)
Nov 13, 2020

Ten-Year Analysis of Low-Dose Glucocorticoids in early RA

Abstract #1998 by C. Roubille et al from Montpellier, France is a 10-year prospective analysis that looked at the risk of severe outcomes related to very low-dose glucocorticoid in early rheumatoid arthritis from the ESPOIR cohort.

Read Article
Dr P Seo notes based on PEXIVAS study while PLEX does not seem to help with AAV, it showed you can drop steroid dose sooner: start pred 1 mg/kg/d but drop down after 1 week to 0.5 mg/kg/d #ACRReview #ACR20 @rheumnow
Nov 10, 2020
Low-dose steroids in RA: what's the harm, right? (You probably know where I'm going with this) ESPOIR 10y data: total events, and severe infections worse with dose and time (cumulative 8.4g ≡ 5mg/d) No doubt some residual confounding, but real risk! #ACR20 ABST1998 @RheumNow
David Liew drdavidliew ( View Tweet)
Nov 09, 2020
What would you use next? sero+ RA new keratitis requiring prednisone and now also 20 SJC. New rheumatoid nodules. Pt has been on triple csDMARDs + Leflunomide, then 2 JAKi and 2 TNFi also with MTX each time. All Rx works for 6 months then relapse.
Janet Pope Janetbirdope ( View Tweet)
Nov 09, 2020
Summary of #ACR20 part B: - The future is bright with many trainees producing great research per Dr. Diane Karen - Belimumab (phase III) reduced proteinuria, improved renal for, and helped w/ tapering of GC in pts w/ lupus nephritis but more infect in GC group @RheumNow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

Nov 09, 2020
2020 #ACR20 RA guidelines were against steroid usage in RA. ESPOIR French cohort: 10 years of very low dose GC show increase events (death/CVD/fracture/severe ifn) even on low doses. HR increases every year. Cum GC dose-effect esp ifn, CVD.
Eric Dein ejdein1 ( View Tweet)
Nov 09, 2020
When you give IA steroids for knee OA how long do you tell pts it will work for @RheumNow #ACR20 @CRASCRRheum abstr#1650

Janet Pope Janetbirdope ( View Tweet)

Nov 09, 2020
×